
News Release

For Immediate Release

4 October 2013

Contact: **Tricia Thompson**
Business Development
+1 (610) 539-3670

PluroGen Therapeutics, Inc. Files Another New Patent Application for its PluroGel[®] Surfactant Technology

(Norristown, Pennsylvania, USA, 4 October 2013) - PluroGen Therapeutics, Inc., a leader in advanced wound care solutions, announced today that it filed another new patent application for its PluroGel[®] Surfactant Technology Product Line. This new patent application is intended to protect the Company's flagship PluroGel[®] Product Line in a multi-billion segment of the Advanced Wound Care Market.

Commenting on the new patent filing, PluroGen President & CEO, Neal G. Koller, said "This is another milestone achievement for PluroGen. We now have multiple patent applications filed just for our PluroGel[®] Surfactant Technology. This new application adds to our Intellectual Property Plan which now maps our protection potential to 2033. Each of these patent applications has the possibility to expand protection for the Company's business and increases shareholder value. With this filing, the opportunity to have product exclusivity in such a large market segment is very exciting."

About PluroGen Therapeutics, Inc.

PluroGen Therapeutics, Inc. is a burn, wound, and skin care company providing clinically advanced and superior products from its multiple, patent-protected technology platforms. The Company's primary platform is its core PluroGel[®] surfactant technology which provides products with paradigm-shifting, superior and differentiated Core, Bio-Physical, and Performance Functions resulting in unique and advantaged Multi-Function products. Products based on PluroGel[®] are University developed and are in routine use, having shown superior results on more than 12,000 patients in two different patient populations- severe burns and non-healing wounds. PluroGen's three technology platforms are configured to deliver a variety of medicinal and beneficial compounds covering the six key areas of treatment in tissue management and healing: 1. Cleansing; 2. Anti-Infection; 3. Reduced Pain; 4. Anti-Inflammation; 5. Tissue salvage; 6. Tissue regeneration. PluroGen has a strong new product pipeline and its senior management, operations team, boards and principal investigators are all recognized global, commercial and clinical leaders in PluroGen's target markets of burn and wound care.

More information can be found on the company web site at www.plurogen.com. For PluroGen Investor Information please call +1 (610) 539-3670.

Safe Harbor Statement:

The statements in the press release that relate to PluroGen's (the company) expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the company's actual operating results, performance, business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.